Effectiveness of HCQS as prophylaxis for Covid 19 infection: Max begins study on its 10,000 healthcare workers

This is the first study involving Covid 19 that was approved by ICMR. This is also the first study from India to be registered on clinicaltrials.gov a global registry for clinical trials.

''Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, the clinicians and scientists community have been in a race to research various aspects of this disease to explore possible prevention and treatment aspects. It is only clinical research that will help prevention of further spread of this disease. The main aim is to reach out to maximum number of HCWs, follow up on incidence of COVID in HCWs and understand the disease pattern in relation to Hydroxy-chloroquine in COVID prevention.'' said Dr Sujeet Jha, Principal Investigator, Principal Director, Endocrinology and Diabetes at Max Healthcare.

Abhay Soi, Chairman Max Healthcare added ''Max Healthcare has always strived to be at the fore-front of medical research and this study will greatly add to our knowledge regarding the role of HCQS in preventing Covid 19 amongst the Healthcare Workers (HCW's) and other higher risk groups. We are hopeful that this will be our small but significant contribution in the global fight against Covid 19''

The results of the study are likely to be published in another 3 weeks.